Poland’s Mabion Gets €30m R&D Loan
Hopes To Be Among The First EU Firms With Biosimilar Rituximab
After receiving a €30m loan from the European Investment Bank, Mabion believes it could be among the first EU-based companies to introduce biosimilar rituximab into the European market.
